Because of heightened genomic instability, cancer cells often have a complex karyotype with many gains and losses in gene copy number. Although comparative genome hybridization (CGH) technologies now enable the mapping of copy number gain or loss at high resolution, the genomic regions pinpointed in such studies are still quite large and may contain tens or even hundreds of genes. A key question that often remains to be answered is which of the many genes in these regions are the "drivers" of the oncogenic phenotype and which are "passengers" whose altered expression does not contribute to the genesis of the cancer. In an elegant study in this issue, Zender et al. (2008) describe an integrative genomics approach to identify the true drivers of oncogenicity in regions of copy number loss in hepatocellular carcinoma, leading to the identification of new tumor suppressor genes.
Zender et al. began by generating high-resolution array CGH maps for 98 human hepatocellular carcinomas (Figure 1) . They concentrated on small (<5 MB) recurrent deletions because such focal deletions are most likely to contain tumor suppressor genes. In total, 58 recurrent deletions were identified, together harboring 362 candidate tumor suppressor genes. To ask which of these genes are relevant to liver carcinogenesis, the authors turned to a previously established mouse model for this disease, consisting of murine embryonic hepatocytes immortalized by loss of the tumor suppressor p53 and expression of the c-Myc oncogene (two events that frequently occur in human hepatocellular carcinoma). Although these hepatocytes are immortal, they do not form tumors in mice and can only be induced to become tumorigenic by introduction of additional oncogenes or tumor suppressor genes (Xue et al., 2008; Zender et al., 2005 Zender et al., , 2006 . To ask which of the 362 candidate human tumor suppressor genes drive the oncogenic process, the authors first identified mouse orthologs for 301 of these genes and obtained retroviral vectors to deliver short hairpin RNAs (shRNAs) to knock down these genes. In a pilot experiment, the authors tested "positive control" shRNAs corresponding to two components of the When pools of shRNAs targeting the candidate tumor suppressor genes were screened in this assay, a striking induction of tumorigenicity (seven out of 13 pools tested yielded tumors) was seen, whereas none of the ten pools of randomly selected shRNAs caused tumor growth. This result strongly suggested that the genomic deletions found in the human tumors are relevant to the genesis of hepatocellular carcinoma. The representation of the shRNA vectors in the mouse tumors was then compared to their original representation in the pools. An enrichment of a specific shRNA in a tumor was taken as evidence that the shRNA conferred a growth advantage in vivo. With this approach, a total of 36 shRNAs were identified that were enriched at least 2.5-fold over their representation in the initial plasmid pools. A selection of these shRNAs was individually validated for enhanced tumor growth in vivo, yielding a total of six genes whose suppression by multiple independent shRNAs markedly enhanced tumorigenicity of immortalized hepatocytes: Pten, Xpo4, Ddx20, Gjd4, Fstl5, and Nrsn2. Of these, only the lipid phosphatase PTEN has previously been implicated in human cancer.
RnAi Delivers Insights into Liver cancer
Most enriched in the screen was Xpo4, encoding Exportin 4, a member of a family of nuclear transporters, known to export Smad3 (a component of TGFβ signaling) and Eif5a1 and Eif5a2 (two closely related translation initiation factors) from the nucleus. Indeed, knockdown of Xpo4 in hepatocytes leads to an increase in nuclear Smad3, and a concomitant upregulation of bona fide TGFβ target genes. This effect on TGFβ signaling appears to be sufficient explanation for the observed enhancement of tumorigenicity due to Xpo4 knockdown. Nevertheless, the authors did notice that one of the genes encoding the other substrate of XPO4, EIF5A2, is often amplified in human cancer, including in 22 of the 98 human hepatocelluar carcinomas studied. Indeed, overexpression of Eif5a2, but not Eif5a1, triggered oncogenic transformation of the c-Mycexpressing p53-deficient hepatocytes, suggesting that Xpo4 not only targets Smad3 to modulate tumorigenicity but also targets Eif5a2. Remarkably, when the authors searched a database of gene copy number alterations in breast cancer, they found that XPO4 is deleted in over 30% of tumors and that this deletion is associated with poor survival. Moreover, the gene encoding the XPO4 substrate EIF5A2 was found to be present in a breast cancer amplicon. Together, this study therefore defines a new oncogenic signaling pathway consisting of XPO4 and EIF5A2.
Perhaps the most surprising aspect of this study is the large number of tumor suppressor genes that were identified. This is especially striking if one considers that the authors used a highly constrained model system to search for genes that enhance tumorigenicity and not all knockdown vectors yield sufficient knockdown to produce a phenotype. It is possible that in another genetic background with more knockdown vectors, yet other genes could be identified.
The identification of an oncogenic signaling pathway involved in protein transport across the nuclear membrane is unexpected, but not without precedent. The gene encoding the nucleoporin NUP98 is a recurring target of translocations in cancer. Among the fusion partners of NUP98 are homeobox transcription factors, a topoisomerase, and an RNA helicase. For instance, NUP98-HOXD13 fusions have been identified in patients with myelodysplastic syndrome, acute myelogenous leukemia, and chronic myeloid leukemia blast crisis (Moore et al., 2007) .
Recently, Firestein et al. (2008) used a related approach to identify new relevant genes for colon cancer. In that study, the authors first screened for genes whose suppression could inhibit both proliferation and WNT signaling in human colon cancer cells. The list of High-resolution array comparative genome hybridization (CGH) of a panel of hepatocellular carcinomas allowed the identification of a number of genes in areas of recurrent copy number loss. Knockdown vectors delivering short hairpin RNAs (shRNAs) were generated against the murine orthologs of these candidate tumor suppressor genes. These vectors were then introduced into immortal but nontumorigenic murine hepatocytes and injected into mice. shRNAs capable of producing a tumorigenic phenotype are likely tumor suppressor genes in hepatocellular carcinoma.
candidate genes was then compared to a list of genes that are located in regions of copy number gain in colon cancer, allowing the identification of cyclin-dependent kinase 8 (CDK8) as a new colon cancer oncogene (Firestein et al., 2008) Zender, L., Xue, W., Zuber, J., Semighini, C.P., Krasnitz, A., Ma, B., Zender, P., Kubicka, S., Luk, J.M., Schirmacher, P., et al. (2008) . Cell, this issue.
Wnt signaling has been intensively studied by bone biologists since the discovery that loss-of-function mutations in low-density lipoprotein receptor-related protein 5 (LRP5), a coreceptor for Wnt ligands, underlie the hereditary disease osteoporosis pseudoglioma (OPPG) (Gong et al., 2001) . Conversely, gainof-function mutations in LRP5 cause high bone mass syndromes in humans (Boyden et al., 2002; Little et al., 2002) . Additional studies have implicated Wnt signaling in the production and function of osteoblasts (bone-forming cells) including genetic deletion of β-catenin, a central component of the canonical Wnt pathway, which results in a complete lack of mature osteoblasts in the mouse (Day et al., 2005; Hill et al., 2005; Hu et al., 2005; Rodda and McMahon, 2006) . Therefore, a current prevailing model posits that canonical Wnt signaling via the cell-surface molecule LRP5, or the related protein LRP6, directly controls osteoblast formation or function. However, direct genetic evidence linking the role of LRP5 in bone formation with canonical Wnt signaling in osteoblasts has been lacking. In this issue of Cell, Yadav et al. (2008) provide compelling evidence that Lrp5 indirectly enhances bone formation through inhibition of serotonin production in the mouse duodenum, thereby revealing the existence of a gut-to-bone endocrine axis.
Prior work provided hints that canonical Wnt signaling in bone might not be sufficient by itself to explain the effects of LRP5 mutations on bone mass. Mice lacking Lrp5 in all cells, similar to patients with OPPG, exhibit low bone mass during early postnatal life, owing to decreased osteoblast proliferation and function (Kato et al., 2002 ). Yet, mice lacking β-catenin specifically in more mature osteoblasts due to expression of Cre-recombinase under the control of the collagen I promoter (ColI-Cre) do not display a clear osteoblast phenotype. These mice do show increased formation of osteoclasts (bone-degrading cells) secondary to a decrease in the osteoblast-derived anti-osteoclastogenic factor osteoprotegerin (OPG) (Glass et al., 2005) . This discrepancy suggested that the osteoblast defect caused by Lrp5 deficiency may occur at an earlier stage of osteoblast development than is targeted by the ColI-Cre transgene. Alternatively, Lrp5 may control bone formation either independently of β-catenin or not through direct effects on osteoblasts, or both.
To shed light on the molecular mechanism through which LRP5 controls bone formation, Yadav et al. (2008) performed microarray experiments with RNA extracted from wild-type and Lrp5-deficient mouse bones. They discovered that the most highly expressed gene in mutant bone tissue compared with wildtype was Tph1, which encodes trypto-
